key: cord-0844720-ciwe5ojr
authors: Chen, Yuning; Zhang, Yanan; Yan, Renhong; Wang, Guifeng; Zhang, Yuanyuan; Zhang, Zherui; Li, Yaning; Ou, Jianxia; Chu, Wendi; Liang, Zhijuan; Wang, Yongmei; Chen, Yili; Chen, Ganjun; Wang, Qi; Zhou, Qiang; Zhang, Bo; Wang, Chunhe
title: ACE2-Targeting Monoclonal Antibody as Potent and Broad-Spectrum Coronavirus Blocker
date: 2021-08-19
journal: bioRxiv
DOI: 10.1101/2020.11.11.375972
sha: dc3e99974afb555eba679cf2ba5fa2706fc09f0a
doc_id: 844720
cord_uid: ciwe5ojr

The evolution of coronaviruses, such as SARS-CoV-2, makes broad-spectrum coronavirus preventional or therapeutical strategies highly sought after. Here we report a human angiotensin-converting enzyme 2 (ACE2)-targeting monoclonal antibody, 3E8, blocked the S1-subunits and pseudo-typed virus constructs from multiple coronaviruses including SARS-CoV-2, SARS-CoV-2 mutant variants (SARS-CoV-2-D614G, B.1.1.7, B.1.351, B.1.617.1 and P.1), SARS-CoV and HCoV-NL63, without markedly affecting the physiological activities of ACE2 or causing severe toxicity in ACE2 “knock-in” mice. 3E8 also blocked live SARS-CoV-2 infection in vitro and in a prophylactic mouse model of COVID-19. Cryo-EM and “alanine walk” studies revealed the key binding residues on ACE2 interacting with the CDR3 domain of 3E8 heavy chain. Although full evaluation of safety in non-human primates is necessary before clinical development of 3E8, we provided a potentially potent and “broad-spectrum” management strategy against all coronaviruses that utilize ACE2 as entry receptors and disclosed an anti-coronavirus epitope on human ACE2.

In the last 20 years, coronaviruses have caused three major transmissible disease 49 outbreaks in human, including severe acute respiratory syndrome (SARS) 1 , Middle 50

East respiratory syndrome (MERS) 2 and coronavirus disease 2019 (COVID-19) 3, 4 . 51

One of the challenges to control coronaviruses is that they evolve constantly, even 52 though slower than HIV and influenza 5 . Analyses of over 28,000 gene sequences of 53 SARS-CoV-2 spike protein (S-protein) in May 2020 revealed a D614G amino acid 54 substitution (SARS-CoV-2-D614G) that was rare before March 2020, but increased 55 greatly in frequency as the pandemic spread worldwide, reaching over 74% of all 56 published sequences by June 2020 6 The key to developing broad-spectrum coronavirus therapeutics is to identify 66 broad-spectrum anti-viral targets. Although RNA polymerase is a broad anti-RNA virus 67 target, it suffers from low specificity and efficacy 11, 12 . By employing a multi-68 dimensional approach, Gordon et al. proposed a set of potential "pan" viral target for 69 coronaviruses, but the druggability of these targets are yet to be evaluated 13 . ACE2 70 fusion proteins can act as decoy receptors to trap SARS-CoV-2 14, 15 , but the affinity and 71 developability of these proteins are generally less than antibodies. Recently, Rappazzo 72 was 60-fold less potent than 3E8, as suggested by the difference between their IC50 159 values (2.3 vs. 0.04 nM), even though both completely abolished SARS-CoV-2 160 replication at high concentrations (Fig. 4a) . (Fig. 4c ). In comparison, the viral loads in B38-treated mice were only about 174 5 times lower than that of control mice. Thus, application of 3E8 achieved significantly 175 greater anti-viral effects than that of B38 in the COVID-19 mouse model we employed. 176 177 3E8 has no effects on ACE2's catalytic activities or causes toxicity in "knock-in" mice 178

Since ACE2 plays important roles in maintaining blood pressure homeostasis in the 179 renin-angiotensin system, we evaluated the safety risks of 3E8 application both in vitro 180 and in vivo. Our studies with both recombinant ACE2 protein and Vero E6 cells 181 suggested that 3E8 had no effects on ACE2's catalytic activities even at 666.7 nM (Fig.  182 5a, b). Furthermore, incubation with 3E8 did not trigger a clear trend of ACE2 183 degradation in Vero E6 cells, as indicated by Western blot (Fig. 5c ). Although 3E8 184 caused time-dependent internalization of ACE2, the levels of membrane-expressed 185 ACE2 were stabilized after 24 h of incubation (Fig. 5d) . In limited number of human 186 ACE2 "knock-in" mice, which express human instead of mouse ACE2, injection of 187 3E8 did not induce noticeable changes in body weights or blood chemistry profiles 188 (supplementary Fig. 3 ). In addition, there were no obvious differences in shape, size or 189 pathological staining of major organs, including hearts, livers, kidneys, spleens and 190 lungs of treated mice (supplementary Fig. 3) . 191 192 3E8 binding epitope on ACE2 is determined by cryo-EM and "alanine walk" studies 193

To characterize the epitope recognized by 3E8 on ACE2, we solved the cryo-EM 194 structure of the ACE2-B 0 AT1 complex bound with 3E8 at an overall resolution of 3.2 195 Å (Fig. 6 ). Each ACE2 molecule in the complex is bound by a 3E8 molecule that 196 extends from the complex like a wing (Fig. 6a) . The heavy chain of 3E8 binds to the 197 peptidase domain of ACE2 mainly through polar interactions between the 198 complementarity-determining region (CDR) 2 and 3 of 3E8 and the N-terminal α1 helix 199 of ACE2 (Fig. 6b) . The loop between α2 and α3 of ACE2, referred to as Loop2-3, also 200 contribute limited interactions with 3E8. The resolution at the interface was improved 201 to 3.4 Å by applying focused refinement, supporting detailed analysis on the 202 interactions between ACE2 and 3E8. The interface can be divided into two clusters. At 203 cluster 1, the side chains of Asp103 and Arg104 of 3E8 are hydrogen (H) bonded with 204 the main chain of Phe28 in α1 helix of ACE2 and the side chain of Tyr83 in Loop2-3 205 of ACE2, respectively (Fig. 6c) . Meanwhile, the main chain atoms of Asp103 and 206

Asp104 of 3E8 form H-bonds with the side chain of Gln24 of ACE2. At cluster 2, Tyr54 207 and Tyr102 of 3E8 interact with Lys31 of ACE2 through cation-π interactions, whereas 208

Asn55 and Lys59 of 3E8 interact with His34 of ACE2 and Glu23 and Gln18 of ACE2, 209 respectively, by forming H-bonds between side chains of these residues (Fig. 6d) . 210

Additionally, we performed "alanine walk" studies and identified Gln24 as the most 211 critical amino acid residue that interact with the CDR3 of 3E8 heavy chain (Fig. 6e) , 212 consistent with the general concept that the CDR3 of heavy chain contributes the most 213 to antigen recognition and binding. Although His34 was indicated by EM study to interact with the CDR2 of the heavy chain, mutation of it to alanine (Fig. 6e ) or other 215 amino acid residues (data not shown) failed to alter the binding of 3E8 to ACE2. 216

Structural alignment of the 3E8/ACE2-B 0 AT1 complex with the previously reported 217 RBD/ACE2-B 0 AT1 complex reveals clash between 3E8 and RBD of SARS-CoV-2 at 218 the binding interface with ACE2 (Fig. 6f) , providing an explanation for the results of 219 competition assays. The binding site of 3E8, SARS-CoV-2, SARS-CoV and HCoV-220 NL63 on ACE2 were summarized 38-40 (Fig. 6g) . Evolutionary tree of 3E8 binding site 221 on ACE2 with different species was also provided (Fig. 6h) To block the entry of coronavirus, either virus-or ACE2-directed strategies can be 226 taken. Targeting viruses directly is theoretically safer but vulnerable to viral evolution. 227

By targeting ACE2 with an RBD-blocking antibody, we achieved broader and more 228 effective suppression against ACE2-dependent coronaviruses without causing severe 229 side effects. Furthermore, we revealed a broad-spectrum anti-coronavirus epitope on 230

The mechanism by which 3E8 is more potent and efficacious than RBD-targeting 232 antibody B38 is not yet fully understood. Limited by the sample size and evaluation 233 using only a prophylactic regimen in a non-lethal animal model, it is premature to 234 conclude that targeting ACE2 is superior to targeting viral RBD in potency or efficacy. 235 B38 is one of the early anti-SARS-CoV-2 antibodies isolated from COVID-19 patients 236 and due to the urgent nature, it was not well engineered with respect to affinity and 237 developability. More head-to-head studies with more ACE2-and RBD-targeting 238 molecules are necessary before drawing any conclusion. 239 ACE2-Fc (or called ACE2-Ig) fusion protein molecules may act as a "decoy" to 240 interfere coronaviruses from binding to endogenous ACE2 molecules ( Fig. 2 and Fig.  241 3). Although ACE2-Fc molecules are broad-spectrum in theory, their binding affinity 242 (to RBDs), specificity and developability are usually lower than antibodies. ACE2-Fc 243 was included in our studies as a control and moderate efficacy was observed in vitro. 244

Thus, ACE2-neutralizing antibody appears to be a more favorable approach than 245 ACE2-Fc fusion protein. 246 "Cocktails" or combination therapies have been currently explored in treating 247 COVID-19 19 . A combination of 3E8 with antibodies recognizing different epitopes 248 (e.g., RBD, NTD and/or glycan) on the viral surface seems a viable option and could 249 be explored in clinic for better efficacy. 250

It is not surprising that no severe side effects or toxicity of 3E8 were observed in 251 vitro or in human ACE2 "knock-in" mice. In vitro, 3E8 did not affect the catalytic 252 activities of ACE2 or trigger significant ACE2 down-regulation. Even though ACE2 253 internalization was overserved, the levels of membrane ACE2 expression were 254 stabilized after 24 h. It is possible that the ACE2 molecules remaining on the membrane 255 are sufficient to maintain the physiological functions of ACE2-expressing cells. 256

Previous studies showed that ACE2 "knockout" mice were viable and healthy in 257 general, even though the contractile dysfunction was found 41 , indicating that ACE2 is 258 not crucial to the survival of animals. Due to limited animal availability, the conclusion 259 from human ACE2 "knock-in" mice should not be overinterpreted. We plan to repeat 260 this study when more animals are commercially available. Moreover, key signs of 261 cardiovascular health, such as pulse pressure and heartbeat rate, cannot be conveniently 262 measured in mice. Thus, the side effects and toxicities of 3E8 should be carefully 263 evaluated in non-human primates before moving to the clinic. Overall, we presented evidence that 3E8 was a promising therapeutic candidate 282 for coronavirus pandemic and believe that it represents a significant conceptual advance 283 CoV-2 variants to recombinant human ACE2 protein were blocked by 3E8. f The IC50 557 values of 3E8 in blocking S1 or RBD binding to human ACE2 protein. 

Additional Materials and Methods Figures. S1 to S6 Table S1 References and notes

The His-tagged S1 proteins of SARS-CoV, HCoV-NL63, SARS-CoV-2, SARS-CoV- Cells were then cultured in suspension in CD medium. After 5 days of culture, the supernatant was collected and purified by Ni-NTA or protein A chromatography. Size exclusion chromatography column (SEC) was used to examine the purity of proteins.

Binding ELISA 96-well Immuno-plates (Greiner) were coated with 2.0 µg/ml of purified recombinant 6×His-tagged human ACE2 protein at 4℃ overnight. After blocking at room temperature for 1 h with 1% casein (Thermo Fisher), plates were washed with PBS containing 0.05% Tween-20, and serial dilutions of 3E8 were added for 1 h incubation.

After washing, goat anti-human IgG conjugated with HRP (AB Clonal Technology, 1:2000 dilution) was added and incubated for 1 h, then TMB substrate (Thermo Fisher Scientific) and 2 M of H2SO4 were added, and OD450 was detected with SpectraMax M5e (Molecular Devices) microplate reader. To measure the binding affinity of S1 proteins to ACE2, 2 μg/ml of various S1 proteins were coated onto plates followed by addition of gradient diluted ACE2-Fc, and goat anti-human IgG conjugated with HRP was used for detection.

Vero E6 and HEK293/ACE2/EGFP cells were harvested and aliquoted into FACS tubes at 5×10 5 cells/tube. The cells were washed with cold staining buffer (PBS+0.1% BSA+0.04% Na3N) and then resuspended in 100 μl of 3E8 at different concentrations.

The cells were kept at 4℃ in the dark for 1 h on a shaker before washed twice. The cells were resuspended in 100 μL of staining buffer containing PE-goat-anti-human IgG 

The ACE2-B 0 AT1 complex was mixed with 3E8 at a molar ratio of 1:1.5 at 4 °C for 1hr before applied to the grids. Aliquots Each stack was exposed for 2.56 s with an exposure time of 0.08 s per frame, resulting in a total of 32 frames per stack. The total dose rate was approximately 50 e -/Å 2 for each stack. The stacks were motion corrected with MotionCor2 2 and binned 2-fold, resulting in a pixel size of 1.087 Å/pixel. Meanwhile, dose weighting was performed 3 .

The defocus values were estimated with Gctf 4 .

Particles were automatically picked using Relion 3.0.6 5-8 from manually selected micrographs. After 2D classification with Relion, good particles were selected and subject to two cycle of heterogeneous refinement without symmetry using cryoSPARC 9 . The good particles were selected and subjected to Non-uniform Refinement (beta) with C1 symmetry, resulting in the 3D reconstruction for the whole structures, which was further subject to 3D classification, 3D auto-refinement and post-processing with Relion with C2 symmetry. To further improve the map quality for interface between 3E8 and ACE2-B 0 AT1 complex, the particles were C2-symmetry expanded and recentered at the location of the interface between 3E8-ACE2 sub-complex. The reextracted dataset was subject to focused refinement with Relion, resulting in the 3D reconstruction of better quality on the binding interface.

The resolution was estimated with the gold-standard Fourier shell correlation 0.143 criterion 10 with high-resolution noise substitution 11 6M18) were used as templates, which were molecular dynamics flexible fitted (MDFF) 12 into the whole cryo-EM map of the complex and the focused-refined cryo-EM map of the 3E8-ACE2 sub-complex, respectively. And the fitted atomic models were further manually adjusted with Coot 13 . Each residue was manually checked with the chemical properties taken into consideration during model building. Several segments, whose corresponding densities were invisible, were not modeled. Structural refinement was performed in Phenix 14 with secondary structure and geometry restraints to prevent overfitting. To monitor the potential overfitting, the model was refined against one of the two independent half maps from the gold-standard 3D refinement approach. Then, the refined model was tested against the other map. Statistics associated with data collection, 3D reconstruction and model building were summarized in supplementary Table 1. "Alanine walk" studies To verify the key residues of ACE2 on binding with 3E8, Q18, E23, Q24, F28, K31, H34 and Y83 on ACE2 were changed into alanine using the overlapped PCR method with PrimeSTAR HS DNA Polymerase (Takara) and the following primers. Plasmids with mutation were expressed in mammalian expression system. After purification by Ni-NTA affinity chromatography, proteins were checked by SDS-PAGE and ELISA. 

Identification of a novel coronavirus in patients with severe 426 acute respiratory syndrome

A new coronavirus associated with human respiratory disease in 431 China

A pneumonia outbreak associated with a new coronavirus of 433 probable bat origin

Genomic mutations and changes in protein secondary 435 structure and solvent accessibility of SARS-CoV-2 (COVID-19 virus)

Spike mutation D614G alters SARS-CoV-2 fitness

Site-440 specific glycan analysis of the SARS-CoV-2 spike

The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity 443 and Antigenicity

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing 445 antibodies elicited by ancestral spike vaccines

Neutralization of variant under investigation B.1.617 with 448 sera of BBV152 vaccinees

Compassionate Use of Remdesivir for Patients with Severe 451

Remdesivir in adults with severe COVID-19: a randomised, 453 double-blind, placebo-controlled, multicentre trial

Comparative host-coronavirus protein interaction networks 456 reveal pan-viral disease mechanisms

An engineered decoy 458 receptor for SARS-CoV-2 broadly binds protein S sequence variants

Intranasal gene therapy to prevent infection by SARS-CoV-2 461 variants

Broad and potent activity against SARS-like viruses by 463 an engineered human monoclonal antibody

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 465 and Is Blocked by a Clinically Proven Protease Inhibitor

Function, and Antigenicity of the SARS-CoV

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid 470 mutational escape seen with individual antibodies

Cross-473 neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

A human monoclonal antibody blocking SARS-CoV-2 infection

A neutralizing human antibody binds to the N-terminal domain of 478 the Spike protein of SARS-CoV-2

A noncompeting pair of human neutralizing antibodies block 480 COVID-19 virus binding to its receptor ACE2

Angiotensin-(1-7): blood, heart, and 482 blood vessels

Angiotensin-converting enzyme 2 and angiotensin-(1-7): an 485 evolving story in cardiovascular regulation

Automated acquisition of cryo-electron micrographs for single particle reconstruction on an FEI Tecnai electron microscope

MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy

Measuring the optimal exposure for single particle cryo-EM using a 2.6 Å reconstruction of rotavirus VP6

Real-time CTF determination and correction

New tools for automated high-resolution cryo-EM structure determination in RELION-3

Accelerated cryo-EM structure determination with parallelisation using GPUs in RELION-2

RELION: implementation of a Bayesian approach to cryo-EM structure determination

A Bayesian view on cryo-EM structure determination

cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination

Optimal determination of particle orientation, absolute hand, and contrast loss in single-particle electron cryomicroscopy

High-resolution noise substitution to measure overfitting and validate resolution in 3D structure determination by single particle electron cryomicroscopy

Flexible fitting of atomic structures into electron microscopy maps using molecular dynamics

Features and development of Coot

PHENIX: a comprehensive Python-based system for macromolecular structure solution